Thrombosis
News
Test for HIT receives CE mark
HIT Confirm, a test used to diagnose heparin-induced thrombocytopenia (HIT), has received the CE mark. This means the test meets regulatory...
Conference Coverage
Few acutely ill hospitalized patients receive VTE prophylaxis
The results “imply that there is a significantly unmet need for effective VTE prophylaxis in both the inpatient and outpatient continuum of care...
Conference Coverage
Protocol helped identify hospitalized children at risk for VTE
SAN DIEGO – Children with hospital-acquired VTE tended to be more medically complex, a single-center study showed.
Conference Coverage
Warfarin dose capping avoided supratherapeutic INRs in hospitalized elderly
SAN DIEGO – Limiting the initial dose of warfarin to 2.5 mg or less for hospitalized patients aged 85 years and older led to significant...
Conference Coverage
Many VTE patients live in fear of the next event
An estimated 41% of patients who experience a VTE fear another clot often or almost all the time.
News
Deaths in patients on emicizumab
Two hemophilia organizations have notified the public of 5 deaths in adult patients receiving emicizumab (Hemlibra). All 5 deaths—occurring in...
News
CHMP recommends approval for generic prasugrel
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization to a...
News
Product approved for hemophilia patients in Japan
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the bispecific factor IXa- and factor X-directed antibody emicizumab (Hemlibra...
News
CHMP recommends rejection for betrixaban
Portola Pharmaceuticals, Inc.
Conference Coverage
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
ORLANDO – Now that reversal is possible prescriptions for the already-popular direct Factor Xa inhibitor, anticoagulants should spike higher.
Conference Coverage
Beware of polypharmacy in patients taking warfarin
SAN DIEGO – The incidence of polypharmacy among patients on warfarin therapy appears to peak at age 75.